| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intracranial Aneurysm | 98 | 2026 | 381 | 18.300 |
Why?
|
| Embolization, Therapeutic | 79 | 2026 | 331 | 14.440 |
Why?
|
| Endovascular Procedures | 87 | 2026 | 628 | 12.140 |
Why?
|
| Stents | 64 | 2026 | 494 | 9.510 |
Why?
|
| Thrombectomy | 67 | 2026 | 253 | 8.590 |
Why?
|
| Stroke | 59 | 2026 | 1206 | 6.050 |
Why?
|
| Brain Ischemia | 37 | 2025 | 418 | 5.590 |
Why?
|
| Treatment Outcome | 165 | 2026 | 5774 | 5.240 |
Why?
|
| Cerebral Angiography | 50 | 2026 | 297 | 4.240 |
Why?
|
| Blood Vessel Prosthesis | 18 | 2024 | 214 | 3.940 |
Why?
|
| Retrospective Studies | 133 | 2026 | 6831 | 3.560 |
Why?
|
| Aneurysm, Ruptured | 16 | 2026 | 81 | 3.440 |
Why?
|
| Tomography, Optical Coherence | 14 | 2024 | 235 | 3.030 |
Why?
|
| Self Expandable Metallic Stents | 10 | 2020 | 33 | 3.010 |
Why?
|
| Thrombosis | 12 | 2022 | 205 | 2.930 |
Why?
|
| Middle Aged | 156 | 2026 | 18166 | 2.890 |
Why?
|
| Radial Artery | 6 | 2022 | 55 | 2.880 |
Why?
|
| Infarction, Middle Cerebral Artery | 12 | 2025 | 87 | 2.710 |
Why?
|
| Aged | 138 | 2026 | 14872 | 2.700 |
Why?
|
| Male | 179 | 2026 | 30894 | 2.510 |
Why?
|
| Humans | 253 | 2026 | 64908 | 2.300 |
Why?
|
| Female | 173 | 2026 | 33853 | 2.290 |
Why?
|
| Catheters | 15 | 2026 | 76 | 2.190 |
Why?
|
| Subarachnoid Hemorrhage | 9 | 2023 | 109 | 1.980 |
Why?
|
| Aged, 80 and over | 65 | 2026 | 5576 | 1.860 |
Why?
|
| Registries | 27 | 2026 | 903 | 1.770 |
Why?
|
| Neurosurgical Procedures | 8 | 2023 | 104 | 1.730 |
Why?
|
| Bone Neoplasms | 6 | 2012 | 121 | 1.550 |
Why?
|
| Carotid Artery, Internal | 9 | 2024 | 68 | 1.540 |
Why?
|
| Central Nervous System Vascular Malformations | 7 | 2023 | 77 | 1.540 |
Why?
|
| Aneurysm, False | 4 | 2022 | 47 | 1.530 |
Why?
|
| Propensity Score | 13 | 2026 | 189 | 1.470 |
Why?
|
| Reperfusion | 5 | 2025 | 37 | 1.370 |
Why?
|
| Dimethyl Sulfoxide | 5 | 2021 | 15 | 1.350 |
Why?
|
| Middle Cerebral Artery | 6 | 2024 | 51 | 1.340 |
Why?
|
| Adult | 76 | 2026 | 17282 | 1.310 |
Why?
|
| Vertebral Artery | 4 | 2020 | 29 | 1.260 |
Why?
|
| Follow-Up Studies | 28 | 2026 | 2483 | 1.250 |
Why?
|
| Mechanical Thrombolysis | 7 | 2025 | 36 | 1.230 |
Why?
|
| Cone-Beam Computed Tomography | 8 | 2018 | 71 | 1.200 |
Why?
|
| Platelet Aggregation Inhibitors | 9 | 2026 | 233 | 1.180 |
Why?
|
| Cerebral Arteries | 5 | 2024 | 41 | 1.110 |
Why?
|
| Polyvinyls | 5 | 2021 | 19 | 1.090 |
Why?
|
| Tomography, X-Ray Computed | 18 | 2025 | 1656 | 1.070 |
Why?
|
| Angiography, Digital Subtraction | 13 | 2021 | 138 | 1.050 |
Why?
|
| Fibrinolytic Agents | 7 | 2025 | 176 | 0.900 |
Why?
|
| Cerebral Hemorrhage | 5 | 2025 | 100 | 0.850 |
Why?
|
| Arterial Occlusive Diseases | 4 | 2022 | 67 | 0.840 |
Why?
|
| Prospective Studies | 24 | 2025 | 3303 | 0.840 |
Why?
|
| Carotid Stenosis | 2 | 2022 | 99 | 0.840 |
Why?
|
| Carotid Arteries | 2 | 2022 | 63 | 0.810 |
Why?
|
| Disease Models, Animal | 9 | 2025 | 2285 | 0.810 |
Why?
|
| Basilar Artery | 3 | 2024 | 33 | 0.810 |
Why?
|
| Postoperative Complications | 10 | 2025 | 1313 | 0.800 |
Why?
|
| Cerebrovascular Circulation | 6 | 2025 | 183 | 0.790 |
Why?
|
| Heparin | 3 | 2024 | 118 | 0.790 |
Why?
|
| Transverse Sinuses | 1 | 2022 | 6 | 0.770 |
Why?
|
| Angiography | 8 | 2020 | 154 | 0.760 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2023 | 171 | 0.760 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2017 | 32 | 0.740 |
Why?
|
| Osteosarcoma | 2 | 2012 | 48 | 0.740 |
Why?
|
| Lithotripsy | 1 | 2022 | 10 | 0.740 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2025 | 2240 | 0.730 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2023 | 223 | 0.730 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2022 | 19 | 0.720 |
Why?
|
| Vascular Calcification | 1 | 2022 | 26 | 0.710 |
Why?
|
| Intracranial Thrombosis | 2 | 2026 | 28 | 0.710 |
Why?
|
| Cerebral Veins | 3 | 2023 | 37 | 0.680 |
Why?
|
| Vertebroplasty | 2 | 2011 | 8 | 0.660 |
Why?
|
| Preoperative Care | 4 | 2026 | 200 | 0.660 |
Why?
|
| Carotid Artery Diseases | 2 | 2022 | 61 | 0.660 |
Why?
|
| Microscopy | 2 | 2024 | 100 | 0.660 |
Why?
|
| Thoracic Vertebrae | 2 | 2011 | 35 | 0.660 |
Why?
|
| Vasospasm, Intracranial | 3 | 2022 | 30 | 0.660 |
Why?
|
| Intracranial Arteriovenous Malformations | 5 | 2026 | 84 | 0.650 |
Why?
|
| Radiography, Interventional | 4 | 2022 | 82 | 0.650 |
Why?
|
| Anterior Cerebral Artery | 6 | 2026 | 11 | 0.650 |
Why?
|
| Cerebrovascular Disorders | 6 | 2019 | 83 | 0.640 |
Why?
|
| Aspirin | 5 | 2025 | 171 | 0.630 |
Why?
|
| Anticoagulants | 3 | 2024 | 522 | 0.620 |
Why?
|
| Tay-Sachs Disease | 3 | 2025 | 52 | 0.610 |
Why?
|
| Rabbits | 9 | 2022 | 338 | 0.600 |
Why?
|
| Lumbar Vertebrae | 2 | 2011 | 174 | 0.570 |
Why?
|
| Diagnostic Errors | 2 | 2019 | 104 | 0.570 |
Why?
|
| Vascular Grafting | 1 | 2018 | 37 | 0.560 |
Why?
|
| Cerebellum | 2 | 2017 | 94 | 0.550 |
Why?
|
| Neointima | 1 | 2018 | 19 | 0.550 |
Why?
|
| Cerebral Infarction | 6 | 2022 | 84 | 0.540 |
Why?
|
| Thromboembolism | 6 | 2024 | 74 | 0.540 |
Why?
|
| Phosphorylcholine | 1 | 2018 | 45 | 0.530 |
Why?
|
| Young Adult | 16 | 2026 | 4784 | 0.530 |
Why?
|
| Cohort Studies | 17 | 2026 | 2609 | 0.530 |
Why?
|
| Thrombolytic Therapy | 5 | 2025 | 195 | 0.530 |
Why?
|
| Prosthesis Design | 6 | 2024 | 218 | 0.520 |
Why?
|
| Intracranial Hemorrhages | 6 | 2025 | 69 | 0.510 |
Why?
|
| Decision Support Techniques | 2 | 2024 | 193 | 0.500 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 56 | 0.500 |
Why?
|
| Adolescent | 19 | 2026 | 6305 | 0.500 |
Why?
|
| Melanoma | 2 | 2019 | 332 | 0.490 |
Why?
|
| Animals | 30 | 2025 | 21339 | 0.490 |
Why?
|
| Radiography | 7 | 2014 | 556 | 0.490 |
Why?
|
| Feasibility Studies | 8 | 2025 | 581 | 0.490 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 318 | 0.480 |
Why?
|
| Dogs | 8 | 2024 | 317 | 0.480 |
Why?
|
| Blood Vessels | 2 | 2015 | 63 | 0.470 |
Why?
|
| Risk Factors | 14 | 2026 | 5407 | 0.470 |
Why?
|
| Sarcoma, Ewing | 2 | 2012 | 13 | 0.470 |
Why?
|
| Vertebral Artery Dissection | 1 | 2015 | 22 | 0.460 |
Why?
|
| Time Factors | 12 | 2025 | 3757 | 0.460 |
Why?
|
| Equipment Design | 6 | 2024 | 359 | 0.460 |
Why?
|
| Device Removal | 4 | 2020 | 64 | 0.460 |
Why?
|
| Bradycardia | 2 | 2016 | 33 | 0.460 |
Why?
|
| Blood Vessel Prosthesis Implantation | 4 | 2024 | 278 | 0.450 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2014 | 6 | 0.440 |
Why?
|
| Algorithms | 2 | 2017 | 1040 | 0.430 |
Why?
|
| Time-to-Treatment | 6 | 2025 | 133 | 0.430 |
Why?
|
| Intracranial Embolism | 3 | 2021 | 41 | 0.430 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2014 | 31 | 0.430 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 403 | 0.430 |
Why?
|
| Genetic Therapy | 5 | 2025 | 831 | 0.430 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2023 | 297 | 0.420 |
Why?
|
| Dependovirus | 4 | 2025 | 745 | 0.410 |
Why?
|
| Bone Cements | 2 | 2011 | 17 | 0.400 |
Why?
|
| Prostheses and Implants | 2 | 2016 | 71 | 0.390 |
Why?
|
| Giant Cell Tumor of Bone | 2 | 2010 | 8 | 0.390 |
Why?
|
| Catheterization | 4 | 2019 | 111 | 0.390 |
Why?
|
| Child | 11 | 2025 | 4614 | 0.390 |
Why?
|
| Skull | 1 | 2013 | 52 | 0.380 |
Why?
|
| Chondrosarcoma | 1 | 2012 | 7 | 0.380 |
Why?
|
| Humerus | 1 | 2012 | 11 | 0.380 |
Why?
|
| Pituitary Neoplasms | 1 | 2012 | 21 | 0.380 |
Why?
|
| Rectal Neoplasms | 1 | 2014 | 138 | 0.380 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 219 | 0.380 |
Why?
|
| Leukoaraiosis | 3 | 2019 | 45 | 0.370 |
Why?
|
| Aneurysm, Infected | 1 | 2012 | 13 | 0.370 |
Why?
|
| Replantation | 1 | 2012 | 11 | 0.370 |
Why?
|
| Adenoma | 1 | 2012 | 68 | 0.370 |
Why?
|
| Computed Tomography Angiography | 5 | 2024 | 140 | 0.360 |
Why?
|
| Blood Platelets | 4 | 2022 | 108 | 0.360 |
Why?
|
| Infarction, Anterior Cerebral Artery | 2 | 2025 | 3 | 0.350 |
Why?
|
| Myofibromatosis | 1 | 2011 | 1 | 0.350 |
Why?
|
| Cervical Vertebrae | 1 | 2013 | 120 | 0.350 |
Why?
|
| Eating | 2 | 2022 | 138 | 0.350 |
Why?
|
| Angiofibroma | 1 | 2011 | 2 | 0.350 |
Why?
|
| Reflex | 1 | 2011 | 27 | 0.340 |
Why?
|
| Fractures, Compression | 1 | 2011 | 9 | 0.340 |
Why?
|
| Predictive Value of Tests | 5 | 2024 | 1104 | 0.330 |
Why?
|
| Aortography | 1 | 2011 | 58 | 0.330 |
Why?
|
| Random Allocation | 4 | 2020 | 200 | 0.330 |
Why?
|
| Foreign Bodies | 1 | 2011 | 55 | 0.330 |
Why?
|
| Spinal Fractures | 1 | 2011 | 41 | 0.330 |
Why?
|
| Postoperative Hemorrhage | 1 | 2011 | 40 | 0.330 |
Why?
|
| Ulna | 1 | 2010 | 5 | 0.330 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2011 | 51 | 0.330 |
Why?
|
| Radius | 1 | 2010 | 19 | 0.320 |
Why?
|
| Retreatment | 5 | 2023 | 43 | 0.320 |
Why?
|
| Coronary Vessels | 2 | 2023 | 123 | 0.320 |
Why?
|
| Shoulder Injuries | 1 | 2010 | 10 | 0.320 |
Why?
|
| India | 11 | 2014 | 164 | 0.320 |
Why?
|
| Models, Anatomic | 3 | 2023 | 62 | 0.310 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 165 | 0.310 |
Why?
|
| Proof of Concept Study | 2 | 2020 | 39 | 0.310 |
Why?
|
| Incidence | 6 | 2025 | 1413 | 0.290 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2008 | 7 | 0.290 |
Why?
|
| beta-Hexosaminidase alpha Chain | 2 | 2025 | 20 | 0.290 |
Why?
|
| Diverticulum | 1 | 2008 | 12 | 0.290 |
Why?
|
| Duodenal Diseases | 1 | 2008 | 15 | 0.290 |
Why?
|
| Fractures, Bone | 1 | 2010 | 138 | 0.280 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2008 | 48 | 0.280 |
Why?
|
| Spinal Fusion | 1 | 2010 | 156 | 0.280 |
Why?
|
| Brain | 7 | 2023 | 1597 | 0.280 |
Why?
|
| Perfusion Imaging | 3 | 2025 | 22 | 0.280 |
Why?
|
| Genetic Vectors | 3 | 2025 | 913 | 0.280 |
Why?
|
| Cerebral Revascularization | 3 | 2019 | 30 | 0.280 |
Why?
|
| Posterior Cerebral Artery | 2 | 2024 | 13 | 0.270 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2011 | 223 | 0.270 |
Why?
|
| Magnetic Resonance Angiography | 4 | 2021 | 186 | 0.270 |
Why?
|
| Endothelium, Vascular | 2 | 2020 | 177 | 0.270 |
Why?
|
| Machine Learning | 3 | 2025 | 192 | 0.260 |
Why?
|
| Child, Preschool | 5 | 2025 | 2059 | 0.260 |
Why?
|
| White Matter | 2 | 2020 | 124 | 0.260 |
Why?
|
| Severity of Illness Index | 6 | 2025 | 1557 | 0.260 |
Why?
|
| Reflex, Trigeminocardiac | 2 | 2016 | 5 | 0.250 |
Why?
|
| Meningeal Arteries | 2 | 2016 | 12 | 0.250 |
Why?
|
| Tissue Plasminogen Activator | 6 | 2024 | 126 | 0.240 |
Why?
|
| Biopsy, Needle | 2 | 2007 | 134 | 0.240 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2026 | 27 | 0.240 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2020 | 699 | 0.240 |
Why?
|
| Adenosine Monophosphate | 1 | 2026 | 30 | 0.240 |
Why?
|
| Muscle Neoplasms | 1 | 2005 | 9 | 0.240 |
Why?
|
| Hyperplasia | 2 | 2018 | 90 | 0.240 |
Why?
|
| Constriction, Pathologic | 2 | 2025 | 132 | 0.230 |
Why?
|
| Hexosaminidase A | 1 | 2025 | 6 | 0.230 |
Why?
|
| Angioplasty, Balloon | 2 | 2018 | 55 | 0.230 |
Why?
|
| Gangliosidoses, GM2 | 1 | 2025 | 18 | 0.230 |
Why?
|
| Sandhoff Disease | 1 | 2025 | 36 | 0.230 |
Why?
|
| Age Factors | 5 | 2024 | 1580 | 0.220 |
Why?
|
| Social Class | 1 | 2026 | 138 | 0.220 |
Why?
|
| Multiple Myeloma | 1 | 2010 | 365 | 0.220 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2025 | 26 | 0.220 |
Why?
|
| Off-Label Use | 1 | 2024 | 14 | 0.210 |
Why?
|
| Platelet Function Tests | 1 | 2024 | 11 | 0.210 |
Why?
|
| Moyamoya Disease | 1 | 2024 | 13 | 0.210 |
Why?
|
| Swine | 3 | 2020 | 396 | 0.210 |
Why?
|
| Equipment Failure Analysis | 2 | 2015 | 78 | 0.210 |
Why?
|
| Recurrence | 3 | 2026 | 655 | 0.210 |
Why?
|
| Carotid Artery, Common | 2 | 2021 | 30 | 0.210 |
Why?
|
| Anesthesia, General | 1 | 2024 | 47 | 0.210 |
Why?
|
| User-Computer Interface | 1 | 2024 | 125 | 0.210 |
Why?
|
| Hematoma | 1 | 2024 | 82 | 0.200 |
Why?
|
| Combined Modality Therapy | 4 | 2024 | 371 | 0.200 |
Why?
|
| Balloon Occlusion | 1 | 2023 | 11 | 0.200 |
Why?
|
| Robotics | 1 | 2024 | 86 | 0.200 |
Why?
|
| Arteriovenous Fistula | 1 | 2023 | 42 | 0.200 |
Why?
|
| Vascular Remodeling | 2 | 2020 | 23 | 0.190 |
Why?
|
| Erythrocytes | 2 | 2021 | 146 | 0.190 |
Why?
|
| Cranial Sinuses | 1 | 2022 | 13 | 0.190 |
Why?
|
| Tinnitus | 1 | 2022 | 16 | 0.190 |
Why?
|
| Peptide Fragments | 1 | 2025 | 416 | 0.190 |
Why?
|
| Radiosurgery | 2 | 2013 | 67 | 0.190 |
Why?
|
| Artifacts | 2 | 2014 | 126 | 0.190 |
Why?
|
| Recovery of Function | 4 | 2024 | 289 | 0.190 |
Why?
|
| Bone Transplantation | 2 | 2012 | 31 | 0.190 |
Why?
|
| Aneurysm | 2 | 2020 | 58 | 0.180 |
Why?
|
| Subarachnoid Space | 1 | 2022 | 15 | 0.180 |
Why?
|
| Open Bite | 1 | 2021 | 1 | 0.180 |
Why?
|
| Femoral Artery | 1 | 2022 | 104 | 0.180 |
Why?
|
| Suction | 2 | 2025 | 33 | 0.180 |
Why?
|
| Risk Assessment | 5 | 2024 | 2092 | 0.180 |
Why?
|
| Nerve Block | 1 | 2022 | 56 | 0.170 |
Why?
|
| Smoking | 2 | 2025 | 860 | 0.170 |
Why?
|
| Pancreatic Elastase | 2 | 2020 | 32 | 0.170 |
Why?
|
| Databases, Factual | 3 | 2021 | 885 | 0.170 |
Why?
|
| Robotic Surgical Procedures | 1 | 2024 | 172 | 0.170 |
Why?
|
| Embolism | 1 | 2021 | 41 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2022 | 114 | 0.170 |
Why?
|
| Fibrin | 4 | 2021 | 19 | 0.170 |
Why?
|
| Range of Motion, Articular | 2 | 2012 | 113 | 0.170 |
Why?
|
| Clinical Decision-Making | 2 | 2024 | 168 | 0.170 |
Why?
|
| C9orf72 Protein | 1 | 2021 | 114 | 0.170 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 174 | 0.160 |
Why?
|
| Nervous System Diseases | 2 | 2020 | 107 | 0.160 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2021 | 153 | 0.160 |
Why?
|
| Angioplasty | 2 | 2017 | 53 | 0.160 |
Why?
|
| Alloys | 2 | 2016 | 30 | 0.160 |
Why?
|
| Cadaver | 1 | 2020 | 127 | 0.160 |
Why?
|
| Global Health | 1 | 2021 | 180 | 0.150 |
Why?
|
| Cisterna Magna | 1 | 2019 | 17 | 0.150 |
Why?
|
| Arteriovenous Malformations | 1 | 2020 | 45 | 0.150 |
Why?
|
| Metastasectomy | 1 | 2019 | 3 | 0.150 |
Why?
|
| Cryotherapy | 1 | 2019 | 16 | 0.150 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2019 | 8 | 0.150 |
Why?
|
| Neuroprotective Agents | 1 | 2020 | 78 | 0.150 |
Why?
|
| Infant | 3 | 2025 | 1688 | 0.150 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2019 | 56 | 0.150 |
Why?
|
| Compassionate Use Trials | 1 | 2019 | 2 | 0.150 |
Why?
|
| Ischemia | 2 | 2019 | 203 | 0.150 |
Why?
|
| Meningeal Neoplasms | 2 | 2016 | 62 | 0.150 |
Why?
|
| Meningioma | 2 | 2016 | 63 | 0.150 |
Why?
|
| Biomechanical Phenomena | 1 | 2020 | 283 | 0.150 |
Why?
|
| Spiral Cone-Beam Computed Tomography | 1 | 2018 | 2 | 0.150 |
Why?
|
| Basal Ganglia | 1 | 2019 | 34 | 0.150 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2019 | 49 | 0.150 |
Why?
|
| Hemodynamics | 1 | 2020 | 251 | 0.150 |
Why?
|
| Brachiocephalic Trunk | 1 | 2018 | 15 | 0.140 |
Why?
|
| Staining and Labeling | 1 | 2019 | 128 | 0.140 |
Why?
|
| Forecasting | 1 | 2019 | 230 | 0.140 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 2 | 2024 | 16 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.140 |
Why?
|
| Ophthalmic Artery | 1 | 2017 | 6 | 0.140 |
Why?
|
| Sheep | 3 | 2025 | 189 | 0.140 |
Why?
|
| Corpus Callosum | 1 | 2018 | 41 | 0.140 |
Why?
|
| Transduction, Genetic | 1 | 2019 | 242 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2012 | 372 | 0.140 |
Why?
|
| Choroid | 1 | 2017 | 17 | 0.130 |
Why?
|
| Vascular Patency | 1 | 2018 | 134 | 0.130 |
Why?
|
| Phosphorus | 1 | 2017 | 16 | 0.130 |
Why?
|
| Headache | 2 | 2015 | 57 | 0.130 |
Why?
|
| Choline | 1 | 2017 | 23 | 0.130 |
Why?
|
| Platelet Factor 4 | 1 | 2017 | 12 | 0.130 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 1690 | 0.130 |
Why?
|
| Gene Transfer Techniques | 1 | 2019 | 324 | 0.130 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 49 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 207 | 0.130 |
Why?
|
| Bayes Theorem | 1 | 2017 | 125 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 220 | 0.130 |
Why?
|
| Sphygmomanometers | 1 | 2016 | 2 | 0.120 |
Why?
|
| Lymphangiectasis, Intestinal | 2 | 1997 | 3 | 0.120 |
Why?
|
| Antibodies | 1 | 2017 | 187 | 0.120 |
Why?
|
| Patient Transfer | 1 | 2017 | 92 | 0.120 |
Why?
|
| Fiber Optic Technology | 1 | 2016 | 22 | 0.120 |
Why?
|
| Surface Properties | 1 | 2017 | 284 | 0.120 |
Why?
|
| Blood Pressure Determination | 1 | 2016 | 39 | 0.120 |
Why?
|
| Biopsy | 2 | 2017 | 454 | 0.120 |
Why?
|
| Gene Expression | 1 | 2019 | 856 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 450 | 0.120 |
Why?
|
| Prognosis | 5 | 2024 | 1775 | 0.120 |
Why?
|
| Porphyria, Acute Intermittent | 1 | 1996 | 2 | 0.120 |
Why?
|
| Chloroquine | 1 | 1996 | 57 | 0.120 |
Why?
|
| Catheterization, Peripheral | 1 | 2016 | 50 | 0.120 |
Why?
|
| Peptides | 1 | 2020 | 590 | 0.120 |
Why?
|
| Shear Strength | 1 | 2015 | 18 | 0.120 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 1996 | 20 | 0.120 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2015 | 8 | 0.120 |
Why?
|
| Hospitals | 2 | 2017 | 385 | 0.120 |
Why?
|
| Tissue Scaffolds | 1 | 2016 | 90 | 0.120 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 1995 | 53 | 0.110 |
Why?
|
| Disease Management | 1 | 2017 | 233 | 0.110 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 1995 | 8 | 0.110 |
Why?
|
| RNA, Small Interfering | 1 | 2021 | 980 | 0.110 |
Why?
|
| Dapsone | 1 | 1995 | 9 | 0.110 |
Why?
|
| Atrial Fibrillation | 1 | 2024 | 869 | 0.110 |
Why?
|
| Treatment Failure | 1 | 2015 | 206 | 0.110 |
Why?
|
| Syncope | 1 | 2015 | 41 | 0.110 |
Why?
|
| Tissue Engineering | 1 | 2016 | 148 | 0.110 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2014 | 9 | 0.110 |
Why?
|
| Europe | 2 | 2025 | 199 | 0.110 |
Why?
|
| Drug Hypersensitivity | 1 | 1995 | 27 | 0.110 |
Why?
|
| Occipital Lobe | 1 | 2014 | 17 | 0.110 |
Why?
|
| Infant, Newborn | 5 | 2014 | 1416 | 0.110 |
Why?
|
| Age of Onset | 1 | 2014 | 173 | 0.110 |
Why?
|
| Intervertebral Disc | 1 | 2014 | 21 | 0.110 |
Why?
|
| Biomarkers | 2 | 2017 | 1471 | 0.110 |
Why?
|
| Brain Mapping | 1 | 2015 | 240 | 0.100 |
Why?
|
| Microsurgery | 2 | 2026 | 54 | 0.100 |
Why?
|
| Tertiary Care Centers | 1 | 2014 | 110 | 0.100 |
Why?
|
| Survival Rate | 2 | 2014 | 847 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2016 | 525 | 0.100 |
Why?
|
| Equipment Failure | 1 | 2014 | 63 | 0.100 |
Why?
|
| Urban Population | 1 | 2014 | 201 | 0.100 |
Why?
|
| Peroxidase | 1 | 2014 | 70 | 0.100 |
Why?
|
| Hospitalization | 1 | 2021 | 1386 | 0.100 |
Why?
|
| X-Ray Intensifying Screens | 1 | 2013 | 8 | 0.100 |
Why?
|
| Surgical Wound Infection | 1 | 2014 | 125 | 0.100 |
Why?
|
| United States | 5 | 2026 | 8067 | 0.100 |
Why?
|
| Materials Testing | 1 | 2014 | 88 | 0.100 |
Why?
|
| Patient Selection | 1 | 2016 | 483 | 0.100 |
Why?
|
| Mutation | 1 | 2021 | 2659 | 0.100 |
Why?
|
| Cross Infection | 1 | 2014 | 165 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2014 | 177 | 0.100 |
Why?
|
| Low Back Pain | 1 | 2014 | 112 | 0.100 |
Why?
|
| Telangiectasis | 1 | 2012 | 7 | 0.100 |
Why?
|
| North America | 2 | 2024 | 113 | 0.090 |
Why?
|
| Diaphyses | 1 | 2012 | 4 | 0.090 |
Why?
|
| Circle of Willis | 2 | 2023 | 7 | 0.090 |
Why?
|
| Surgical Instruments | 1 | 2012 | 44 | 0.090 |
Why?
|
| Osteotomy | 1 | 2012 | 20 | 0.090 |
Why?
|
| Shoulder Joint | 1 | 2012 | 30 | 0.090 |
Why?
|
| Kidney | 1 | 2014 | 451 | 0.090 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 242 | 0.090 |
Why?
|
| Limb Salvage | 1 | 2012 | 65 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1276 | 0.090 |
Why?
|
| Walruses | 2 | 2021 | 2 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2024 | 989 | 0.090 |
Why?
|
| Pandemics | 3 | 2021 | 670 | 0.090 |
Why?
|
| Drainage | 2 | 2023 | 153 | 0.090 |
Why?
|
| Trigeminal Nerve | 1 | 2011 | 4 | 0.090 |
Why?
|
| Antitubercular Agents | 1 | 1992 | 82 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 414 | 0.090 |
Why?
|
| Homeostasis | 1 | 2014 | 378 | 0.080 |
Why?
|
| Solvents | 1 | 2011 | 60 | 0.080 |
Why?
|
| Polymethyl Methacrylate | 1 | 2011 | 15 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2025 | 740 | 0.080 |
Why?
|
| Contrast Media | 3 | 2021 | 429 | 0.080 |
Why?
|
| Internal Fixators | 1 | 2010 | 11 | 0.080 |
Why?
|
| Pronation | 1 | 2010 | 4 | 0.080 |
Why?
|
| Supination | 1 | 2010 | 6 | 0.080 |
Why?
|
| Arthrodesis | 1 | 2010 | 16 | 0.080 |
Why?
|
| Wrist Joint | 1 | 2010 | 26 | 0.080 |
Why?
|
| Prevalence | 3 | 2008 | 1437 | 0.080 |
Why?
|
| Ultrasonography | 2 | 2007 | 491 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2010 | 130 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 2697 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2026 | 852 | 0.080 |
Why?
|
| Meningitis | 1 | 1989 | 18 | 0.080 |
Why?
|
| Nanoparticles | 1 | 2015 | 544 | 0.070 |
Why?
|
| Pseudomonas Infections | 1 | 1989 | 74 | 0.070 |
Why?
|
| Pain Measurement | 1 | 2010 | 340 | 0.070 |
Why?
|
| Wound Healing | 1 | 2010 | 193 | 0.070 |
Why?
|
| Ampulla of Vater | 1 | 2008 | 12 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2008 | 7 | 0.070 |
Why?
|
| Sarcoma, Synovial | 1 | 2008 | 6 | 0.070 |
Why?
|
| Pelvic Neoplasms | 1 | 2008 | 10 | 0.070 |
Why?
|
| Acute Disease | 2 | 2020 | 665 | 0.070 |
Why?
|
| Femur Head | 1 | 2008 | 3 | 0.070 |
Why?
|
| Chromosomes, Human, X | 1 | 2008 | 35 | 0.070 |
Why?
|
| Translocation, Genetic | 1 | 2008 | 74 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 1160 | 0.070 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2008 | 64 | 0.070 |
Why?
|
| Tibia | 1 | 2008 | 75 | 0.070 |
Why?
|
| Fasciola hepatica | 1 | 2007 | 1 | 0.070 |
Why?
|
| Liver Abscess | 1 | 2007 | 18 | 0.060 |
Why?
|
| Antigens, Helminth | 1 | 2007 | 9 | 0.060 |
Why?
|
| Echinococcosis, Hepatic | 1 | 2007 | 6 | 0.060 |
Why?
|
| Cattle | 2 | 2019 | 318 | 0.060 |
Why?
|
| Disease Progression | 2 | 2022 | 1213 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 2 | 2021 | 240 | 0.060 |
Why?
|
| beta-Hexosaminidase beta Chain | 1 | 2025 | 8 | 0.060 |
Why?
|
| G(M2) Ganglioside | 1 | 2025 | 15 | 0.060 |
Why?
|
| Fluoroscopy | 2 | 2017 | 67 | 0.060 |
Why?
|
| Collateral Circulation | 1 | 2025 | 28 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 799 | 0.050 |
Why?
|
| Torque | 1 | 2024 | 15 | 0.050 |
Why?
|
| Miniaturization | 1 | 2024 | 10 | 0.050 |
Why?
|
| Postoperative Care | 1 | 2024 | 125 | 0.050 |
Why?
|
| Drug-Eluting Stents | 1 | 2024 | 68 | 0.050 |
Why?
|
| Sex Factors | 1 | 2026 | 990 | 0.050 |
Why?
|
| Sympathectomy | 1 | 2022 | 5 | 0.050 |
Why?
|
| Japan | 1 | 2022 | 64 | 0.050 |
Why?
|
| Subclavian Artery | 1 | 2022 | 26 | 0.050 |
Why?
|
| Cannula | 1 | 2022 | 21 | 0.050 |
Why?
|
| von Willebrand Factor | 1 | 2022 | 10 | 0.050 |
Why?
|
| Dilatation | 1 | 2022 | 34 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2022 | 67 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2022 | 70 | 0.050 |
Why?
|
| Models, Statistical | 2 | 2014 | 309 | 0.050 |
Why?
|
| Intravital Microscopy | 1 | 2022 | 13 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2024 | 211 | 0.050 |
Why?
|
| Drug Administration Routes | 1 | 2021 | 22 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2022 | 109 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2022 | 103 | 0.040 |
Why?
|
| Canada | 1 | 2021 | 152 | 0.040 |
Why?
|
| Hospitals, Low-Volume | 1 | 2021 | 20 | 0.040 |
Why?
|
| Cranial Fossa, Anterior | 1 | 2020 | 1 | 0.040 |
Why?
|
| Hospitals, High-Volume | 1 | 2021 | 36 | 0.040 |
Why?
|
| Arteries | 1 | 2020 | 81 | 0.040 |
Why?
|
| Disks Large Homolog 4 Protein | 1 | 2020 | 21 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2022 | 265 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 71 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 45 | 0.040 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2020 | 45 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2019 | 45 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2021 | 415 | 0.040 |
Why?
|
| Clot Retraction | 1 | 2019 | 3 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2021 | 206 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2019 | 33 | 0.040 |
Why?
|
| Coronary Thrombosis | 1 | 2019 | 21 | 0.040 |
Why?
|
| Hypothermia, Induced | 1 | 2019 | 40 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 405 | 0.040 |
Why?
|
| Video Recording | 1 | 2019 | 139 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2019 | 259 | 0.040 |
Why?
|
| Vestibule, Labyrinth | 1 | 1998 | 6 | 0.040 |
Why?
|
| Models, Animal | 1 | 2019 | 241 | 0.040 |
Why?
|
| Transgenes | 1 | 2019 | 202 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2019 | 162 | 0.040 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 1998 | 33 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1290 | 0.030 |
Why?
|
| Epilepsies, Myoclonic | 1 | 1998 | 2 | 0.030 |
Why?
|
| Diseases in Twins | 1 | 1998 | 56 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2019 | 200 | 0.030 |
Why?
|
| Herpes Zoster | 1 | 1997 | 22 | 0.030 |
Why?
|
| Prolapse | 1 | 2017 | 3 | 0.030 |
Why?
|
| Developing Countries | 1 | 1998 | 87 | 0.030 |
Why?
|
| Alopecia | 1 | 1997 | 28 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2014 | 493 | 0.030 |
Why?
|
| Tourniquets | 1 | 2017 | 6 | 0.030 |
Why?
|
| X-Rays | 1 | 2017 | 46 | 0.030 |
Why?
|
| Epilepsy | 1 | 1998 | 112 | 0.030 |
Why?
|
| Radiation Exposure | 1 | 2017 | 24 | 0.030 |
Why?
|
| Iohexol | 1 | 2016 | 18 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2016 | 27 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 575 | 0.030 |
Why?
|
| Triage | 1 | 2017 | 134 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2017 | 140 | 0.030 |
Why?
|
| Neurons | 1 | 2021 | 941 | 0.030 |
Why?
|
| Echoencephalography | 1 | 2015 | 14 | 0.030 |
Why?
|
| Endoscopy, Digestive System | 1 | 1996 | 32 | 0.030 |
Why?
|
| Dysarthria | 1 | 2015 | 7 | 0.030 |
Why?
|
| Diplopia | 1 | 2015 | 8 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 1996 | 295 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1995 | 32 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 162 | 0.030 |
Why?
|
| Ataxia | 1 | 2015 | 22 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2019 | 518 | 0.030 |
Why?
|
| Molecular Imaging | 1 | 2015 | 52 | 0.030 |
Why?
|
| Genetic Testing | 1 | 1996 | 141 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2014 | 21 | 0.030 |
Why?
|
| Syndrome | 1 | 1995 | 178 | 0.030 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2014 | 48 | 0.030 |
Why?
|
| Permeability | 1 | 2014 | 50 | 0.030 |
Why?
|
| Pregnancy | 3 | 2014 | 2366 | 0.030 |
Why?
|
| Intestinal Mucosa | 2 | 1997 | 250 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 230 | 0.030 |
Why?
|
| Particle Size | 1 | 2016 | 428 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2014 | 25 | 0.030 |
Why?
|
| Gestational Age | 1 | 2014 | 195 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 1994 | 76 | 0.030 |
Why?
|
| Infection Control | 1 | 2014 | 104 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 149 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 1191 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 376 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 292 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 1997 | 384 | 0.020 |
Why?
|
| Capillaries | 1 | 2012 | 31 | 0.020 |
Why?
|
| Echo-Planar Imaging | 1 | 2012 | 34 | 0.020 |
Why?
|
| Radiographic Image Enhancement | 1 | 2013 | 98 | 0.020 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2012 | 5 | 0.020 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2012 | 16 | 0.020 |
Why?
|
| Nanostructures | 1 | 2015 | 187 | 0.020 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 1992 | 2 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1992 | 128 | 0.020 |
Why?
|
| Intestine, Small | 1 | 1992 | 82 | 0.020 |
Why?
|
| Neuroimaging | 1 | 2012 | 162 | 0.020 |
Why?
|
| Tuberculosis | 1 | 1994 | 305 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 1010 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2008 | 17 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 11113 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 897 | 0.010 |
Why?
|
| Knee Joint | 1 | 2008 | 310 | 0.010 |
Why?
|
| Liver | 1 | 2007 | 867 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 702 | 0.010 |
Why?
|
| Cycloleucine | 1 | 1998 | 7 | 0.010 |
Why?
|
| Rana pipiens | 1 | 1998 | 10 | 0.010 |
Why?
|
| Semicircular Canals | 1 | 1998 | 4 | 0.010 |
Why?
|
| Auditory Pathways | 1 | 1998 | 7 | 0.010 |
Why?
|
| Afferent Pathways | 1 | 1998 | 17 | 0.010 |
Why?
|
| Hair Cells, Auditory | 1 | 1998 | 14 | 0.010 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 1998 | 38 | 0.010 |
Why?
|
| Feedback | 1 | 1998 | 91 | 0.010 |
Why?
|
| Twins, Dizygotic | 1 | 1998 | 56 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1998 | 18 | 0.010 |
Why?
|
| Gene Frequency | 1 | 1998 | 122 | 0.010 |
Why?
|
| Duodenoscopy | 1 | 1997 | 3 | 0.010 |
Why?
|
| Twins, Monozygotic | 1 | 1998 | 72 | 0.010 |
Why?
|
| Fetal Death | 1 | 1997 | 15 | 0.010 |
Why?
|
| Lymphatic System | 1 | 1997 | 19 | 0.010 |
Why?
|
| Duodenum | 1 | 1997 | 42 | 0.010 |
Why?
|
| Family Health | 1 | 1998 | 68 | 0.010 |
Why?
|
| Electroencephalography | 1 | 1998 | 149 | 0.010 |
Why?
|
| Genotype | 1 | 1998 | 673 | 0.010 |
Why?
|
| RNA | 1 | 1998 | 426 | 0.010 |
Why?
|
| Endoscopy | 1 | 1995 | 94 | 0.010 |
Why?
|
| Steroids | 1 | 1994 | 55 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1994 | 105 | 0.010 |
Why?
|
| Models, Biological | 1 | 1998 | 1204 | 0.010 |
Why?
|
| Plants, Medicinal | 1 | 1971 | 19 | 0.010 |
Why?
|
| Respiratory Tract Diseases | 1 | 1971 | 39 | 0.010 |
Why?
|
| Plant Extracts | 1 | 1971 | 130 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 1971 | 460 | 0.000 |
Why?
|